Alle Storys
Folgen
Keine Story von AmVac AG mehr verpassen.

AmVac AG

AmVac AG Expands Its Advisory Board with Hartmut Retzlaff, CEO of STADA Arzneimittel AG

Zug (ots)

The Swiss company AmVac AG, a biopharmaceutical
company based in Zug, has announced the expansion of its Advisory
Board. With the acquisition of Hartmut Retzlaff, CEO of STADA
Arzneimittel AG, AmVac now has one of the most successful company
managers in the German pharmaceutical industry on the Board. Hartmut
Retzlaff has been head of STADA AG since 1994 and was responsible for
its successful flotation in 1998. STADA has been listed on the M-Dax
since 2001 and today has a market capitalization of approximately EUR
2.7 billion. STADA focuses on the development and marketing of
products with unpatented active pharmaceutical ingredients in the
health and pharmaceuticals market. In the 2007 fiscal year, STADA
recorded sales of EUR 1.6 billion and a net profit of EUR 105
million.
Melinda-Kinga Karpati, CEO of AmVac AG, says, "In Hartmut Retzlaff
we have acquired one of the most experienced managers for AmVac AG.
We are looking forward to constructive collaboration with him and are
counting on his extensive network."
About AmVac AG
AmVac AG is a biopharmaceutical company based in Switzerland. The
company focuses on the vaccine market which is displaying
above-average growth rates. Its pipeline includes two close-to-market
therapeutic vaccines in the fields of gynecology and urology. Other
innovative vaccines and technologies are under development. The
well-known market research company Frost & Sullivan presented its
sought-after Enabling Technology of the Year Award to AmVac AG in
2006.

Contact:

Ariane Meynert, Head of PR/IR
E-Mail: meynert@amvac.ch
Tel.: +41/41/725'32'34
Mobile: +41/79/793'34'19

Weitere Storys: AmVac AG
Weitere Storys: AmVac AG
  • 12.06.2008 – 08:50

    AmVac AG Begins Research Cooperation with Bayer

    Zug, Catania (ots) - AmVac AG, a Swiss biopharmaceutical company based in Zug, is starting its first research cooperation program with Bayer Innovation GmbH on the development of a new influenza vaccine. Joint research and development work is beginning with the Bayer subsidiary Icon Genetics GmbH on a novel production approach. Antigens are to be produced for the first time in tobacco plants which along with AmVac AG's ...

  • 21.12.2007 – 16:50

    Dr. Wolfgang Schmidt appointed AmVac AG COO

    Zug (ots) - AmVac AG has a new executive officer on board - Dr. Wolfgang Schmidt agreed to join the company in early December to lead its operational business. Dr. Wolfgang Schmidt is a graduated chemist who began his career with Hoechst AG in Frankfurt/Main, Germany. After a variety of stints in pharmaceutical research, he directed the site-management Frankfurt department in the lead generation research segment. ...

  • 07.09.2007 – 14:42

    Ariane Meynert Joins Swiss AmVac AG

    Zug (ots) - As of September 1, 2007 Ariane Meynert is joining Swiss biotech company AmVac AG, Zug, as Managing Director in charge of investor and public relations. Management graduate Meynert comes from TOMORROW FOCUS AG in Munich, a Hubert Burda Medien AG Group company where she was in charge of developing investor and public relations for several years. She previously supervised, in the same function, the ...